siRNA-mediated silencing of survivin inhibits proliferation and enhances etoposide chemosensitivity in acute myeloid leukemia cells

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 12, 2013, Pages 7719-7724

  Karami, Hadi ^a   Baradaran, Behzad ^a   Esfahani, Ali ^a   Estiar, Mehrdad Asghari ^a   Naghavi Behzad, Mohammad ^a   Sakhinia, Masoud ^b   Sakhinia, Ebrahim ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; Etoposide; HL 60; siRNA; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; ETOPOSIDE; INHIBITOR OF APOPTOSIS PROTEIN; MESSENGER RNA; SMALL INTERFERING RNA;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, MYELOID, ACUTE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84893418714     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.12.7719     Document Type: Article

References (31)

1. Adida C, Recher C, Raffoux E, et al (2000). Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol, 111, 196-203.
2. Aoki Y, Cioca DP, Oidaira H, Kamiya J, Kiyosawa K (2003). RNA interference may be more potent than antisense RNA in human cancer cell lines. Clin Exp Pharmacol Physiol, 30, 96-102.
3. Baran Y, Gur B, Kaya P, et al (2007). Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematol, 12, 511-7.
4. Brantl S (2002). Antisense-RNA regulation and RNA interference. Biochim Biophys Acta, 1575, 15-25.
5. Chou TC, Talalay P (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul, 22, 27-55.
6. Church DN, Talbot DC (2012). Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep, 14, 120-8.
7. Coumar MS, Tsai FY, Kanwar JR, Sarvagalla S, Cheung CH (2013). Treat cancers by targeting survivin: just a dream or future reality? Cancer Treat Rev, 39, 802-11.
8. Dai Y, Grant S (2007). Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res, 67, 2908-11.
9. Devi GR (2006). siRNA-based approaches in cancer therapy. Cancer Gene Ther, 13, 819-29.
10. Feng W, Yoshida A, Ueda T (2013). YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells. Biochem Biophys Res Commun, 435, 52-7.
11. Fukuda S, Pelus LM (2006). Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther, 5, 1087-98.
12. Gautrey HL, Tyson-Capper AJ (2012). Regulation of Mcl-1 by SRSF1 and SRSF5 in cancer cells. PLoS One, 7, 51497.
13. High LM, Szymanska B, Wilczynska-Kalak U, et al (2010). The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol, 77, 483-94.
14. Ho MM, Hogge DE, Ling V (2008). MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. Exp Hematol, 36, 433-42.
15. Kang MH, Reynolds CP (2009). Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res, 15, 1126-32.
16. Kelly RJ, Lopez-Chavez A, Citrin D, Janik JE, Morris JC (2011). Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer, 10, 35.
17. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Method. Methods, 25, 402-8.
18. Martins LM, Mesner PW, Kottke TJ, et al (1997). Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood, 90, 4283-96.
19. Miao GY, Lu QM, Zhang XL (2007). Downregulation of survivin by RNAi inhibits growth of human gastric carcinoma cells. World J Gastroenterol, 13, 1170-4.
20. Michels J, Johnson PW, Packham G (2005). Mcl-1. Int J Biochem Cell Biol, 37, 267-71.
21. Montecucco A, Biamonti G (2007). Cellular response to etoposide treatment. Cancer Lett, 252, 9-18.
22. Nakao K, Hamasaki K, Ichikawa T, et al (2006). Survivin downregulation by siRNA sensitizes human hepatoma cells to TRAIL-induced apoptosis. Oncol Rep, 16, 389-92.
23. Paduano F, Villa R, Pennati M, et al (2006). Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther, 5, 179-86.
24. Robak T, Wierzbowska A (2009). Current and emerging therapies for acute myeloid leukemia. Clin Ther, 31, 2349-70.
25. Ryan BM, O'Donovan N, Duffy MJ (2009). Survivin: a new target for anti-cancer therapy. Cancer Treat Rev, 35, 553-62.
26. Shan G (2010). RNA interference as a gene knockdown technique. Int J Biochem Cell Biol, 42, 1243-51.
27. Song H, Xin XY, Xiao F, at al (2008). Survivin gene RNA interference inhibits proliferation, induces apoptosis, and enhances radiosensitivity in HeLa cells. Eur J Obstet Gynecol Reprod Biol, 136, 83-9.
28. Wacheck V, Cejka D, Sieghart W, et al (2006). Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells. Cancer Biol Ther, 5, 1348-54.
29. Yang M, Mattes J (2008). Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs. Pharmacol Ther, 117, 94-104.
30. Zaffaroni N, Daidone MG (2002). Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat, 5, 65-72.
31. Zaffaroni N, Pennati M, Daidone MG (2005). Survivin as a target for new anticancer interventions. J Cell Mol Med, 9, 360-72.